Search Bar & Filters
Found 1399 Actively Recruiting clinical trials
Actively Recruiting
Researchers are studying patients who have had an acute ischemic stroke affecting the basal ganglia and were treated with mechanical thrombectomy. The study aims to understand how often and in what ways cognitive, motor, and sleep problems occur after this treatment. The main focus is on defining these possible dysfunctions in the short and long term after stroke treatment. The study involves patients who have undergone mechanical thrombectomy for stroke in the proximal middle cerebral artery. Participants will be evaluated using tests for cognitive function, movement abilities, and sleep disorders. Specifically, sleep will be studied through polysomnographic examinations. Assessments occur in the acute phase soon after treatment and continue through long-term follow-up. Participants will undergo testing for cognitive, motor, and sleep function within 72 hours after their stroke treatment and at later points to monitor changes over time. The primary outcome is the presence of post-stroke cognitive dysfunction measured shortly after treatment. The research team will closely observe clinical outcomes related to movement and sleep as well. The study is sponsored by Fondazione Policlinico Universitario Agostino Gemelli IRCCS and involves adult participants starting from age 18.
Actively Recruiting
Healthy Volunteer
This research aims to evaluate whether creating dedicated HIV teams in hospitals across ten European countries can increase HIV testing rates among patients showing signs of HIV-related conditions. The study uses a stepped-wedge design, where hospitals switch from routine care to the new intervention in sequence. This approach compares outcomes before and after the teams are in place, helping to understand the impact of the intervention across various locations and medical specialties. The intervention involves establishing local HIV teams led by specialists and supported by nurses and data experts. These teams identify patients needing HIV tests through electronic health records, provide feedback to doctors to encourage testing, offer education to healthcare staff about HIV, reduce stigma, and improve connections to prevention and care services. This program integrates smoothly into regular hospital routines and aims to close gaps in HIV diagnosis. Participants HIV testing rates will be monitored by reviewing records before and after the intervention. Researchers will also assess new HIV diagnoses, changes in testing patterns by country and specialty, and healthcare professionals knowledge and attitudes toward HIV. The study includes ongoing evaluation of how well the teams operate, resource use, and cost-effectiveness. Data collection extends up to several years to observe long-term effects, with continuous monitoring of care access and prevention services.
Actively Recruiting
Researchers are conducting a large-scale observational study to better understand migraine disorders, focusing on both episodic and chronic forms in adult patients recently attending specialized migraine centers in Italy. The study aims to capture the natural history and patient journey of migraine, including demographic and clinical characteristics, treatment adherence, and the impact on daily activities and healthcare resources. Participants will undergo a baseline visit with thorough clinical and neurological examinations and will be followed prospectively with ongoing data collection during routine clinical visits as needed. The study collects detailed information on disease prevalence, patient disability using validated scales MIDAS and HIT-6, pharmacological treatments, medical visits, diagnostic procedures, and the use of health resources. During their participation, which lasts 24 months from their initial visit, patients will provide clinical data through structured interviews and questionnaires. Researchers will measure outcomes such as the dimensions of migraine in Italian headache centers and patients awareness of their condition. This study does not involve experimental treatments but observes standard care and patient experiences over time.
Actively Recruiting
Researchers are evaluating the combination of CGT9486 and sunitinib compared to sunitinib alone in patients with locally advanced, unresectable, or metastatic Gastrointestinal Stromal Tumors GIST. This Phase 3, open-label international trial involves multiple parts, including dose confirmation, drug interaction assessments, and efficacy comparisons. The study also includes substudies focusing on drug-drug interaction potential and first-line treatment in patients with specific genetic mutations KIT exon 9. Approximately 482 patients will participate across these parts.
Actively Recruiting
Researchers are studying the use of spleen shear wave elastography SWE-SSM to help diagnose significant portal hypertension and high-risk esophageal varices in patients with advanced compensated chronic liver disease. The study aims to understand how well SWE-SSM can identify these conditions without affecting patient treatment or disease progression. It also explores how SWE-SSM relates to portal pressure and transient elastography measurements in some patients. During the ultrasound exams that patients normally undergo, spleen elastography will be added if the patient meets study criteria and consents. This additional test is non-invasive and does not change the standard ultrasound procedure or patient care. No treatments or experimental interventions will be given, as the study focuses on collecting clinical data through observation. Participants will have ultrasound exams including both spleen and liver elastography as part of their usual care pathway. Researchers will evaluate measurements related to portal hypertension and esophageal varices over a two-year period. The study monitors the natural course of the disease and gathers data without altering treatments or clinical management.
Actively Recruiting
Researchers are studying changes in the shape of the palate in growing children with different vertical facial growth patterns who have a posterior cross-bite. The study focuses on patients with mixed dentition, skeletal Class I relationship, and who are in the prepubertal stage. The goal is to understand how rapid palatal expander treatment affects the palate morphology among hyperdivergent, hypodivergent, and normodivergent facial types. The treatment involves using a rapid palatal expander device for about 6 months. Patients will be grouped based on their facial divergence patterns. Digital dental casts will be recorded before and after the treatment using an intraoral scanner. Researchers will perform linear measurements and a comprehensive study of the palate shape using a set of 240 landmarks and semi-landmarks. Geometric Morphometric Analysis GMA will compare the palate shape changes among the different groups. Participants will undergo clinical evaluations and have pre-treatment and post-treatment digital records including oral scans and photographs. The primary outcome is to measure morphological changes of the palate after 6 months. Secondary outcomes include detailed shape analysis of the palatal vault among the different facial types. The study requires good quality records and informed consent from participants, with total participation lasting around 6 months.
Actively Recruiting
Researchers are evaluating the diagnostic performance of 68GaBED003 in detecting several types of cancer, including colorectal cancer, gastric cancer, pancreatic ductal adenocarcinoma, invasive lobular breast cancer, and epithelial ovarian cancer. This multi-centre, open-label, single-arm Phase 2 study aims to understand how well this PET imaging agent works in identifying these cancers. Participants receive an injection of 68GaBED003 followed by positron emission tomography PET combined with computed tomography CT imaging during a dedicated visit. The study monitors the diagnostic accuracy of the imaging, assesses tumor uptake of the agent, and evaluates safety and tolerability up to 42 days after injection. The first six participants also help determine optimal imaging timing and dosing. During the study, participants undergo screening, imaging, and safety follow-up, including pregnancy testing for women of childbearing potential. Researchers collect imaging data and monitor for any adverse effects up to 48 hours after injection and continue follow-up assessments for up to 42 days. Overall participation lasts from screening through safety follow-up and post-imaging observation.
Actively Recruiting
Researchers are creating a national registry in Italy to observe and record how multiple myeloma is diagnosed and treated in routine clinical practice. This observational study aims to describe the standard care for patients with multiple myeloma across different hematology centers, reflecting the current situation and variations in treatment and patient characteristics. Both retrospective and prospective data will be collected to provide a comprehensive view. The study involves a non-interventional, multicenter registry that includes patients diagnosed with multiple myeloma since January 1, 2019. Patients are enrolled consecutively during their routine appointments, and data are collected using an electronic platform. Patients participating in other studies may also be included, with baseline and survival data collected during their participation in interventional trials. Hospital visits for data collection occur approximately every six months. Participants will be followed for up to three years, during which researchers will measure overall survival and time to next treatment. Patient-reported outcomes and costs incurred by patients will also be tracked over this period. The study encourages patient involvement and aims to enhance understanding of multiple myeloma care in Italy without altering standard treatment or requiring additional interventions.
Actively Recruiting
Researchers are investigating new treatments for advanced renal cell carcinoma RCC, a type of kidney cancer. This study compares a standard targeted therapy called belzutifan with a combination of belzutifan and another targeted therapy, zanzalintinib. The goal is to find out if adding zanzalintinib helps people with advanced RCC live longer and without their cancer worsening compared to belzutifan alone. Participants will be randomly assigned to one of two groups. One group will take 120 mg of belzutifan orally plus 60 mg of zanzalintinib once daily for about 24 months. The other group will take 120 mg of belzutifan plus a placebo matching zanzalintinib once daily for the same period. Both treatments are given as tablets taken by mouth. During the study, participants will have regular evaluations to monitor their cancers status, side effects, and quality of life. Researchers will use specific measures such as progression-free survival PFS and overall survival OS over up to 50 months. Other assessments include tumor response, duration of response, adverse events, and changes in health questionnaires related to physical function and symptoms. Safety and treatment effects will be carefully tracked throughout the study.
Actively Recruiting
Researchers are investigating new treatments for advanced renal cell carcinoma RCC that has returned after prior therapy. The study aims to find out if the combination of belzutifan and zanzalintinib can help people with recurrent advanced RCC live longer without their cancer worsening compared to the drug cabozantinib. This is a phase 3 randomized trial evaluating these treatments in participants who have experienced recurrence during or after prior anti-PD-1L1 therapy. Participants are randomly assigned to receive either belzutifan plus zanzalintinib taken orally once daily or cabozantinib taken orally once daily. They continue their assigned treatment until certain reasons require stopping the study intervention. The study compares the effects of these treatments on cancer progression and survival among people with advanced RCC who have had disease recurrence after adjuvant therapy. During the study, participants will be regularly monitored for progression-free survival and overall survival for up to about 73 months. Researchers will also assess tumor response, duration of response, adverse events, and quality of life using questionnaires over approximately 25 months. The study involves ongoing evaluations to understand how these treatments affect symptoms, functioning, and overall health during long-term follow-up.
1-10 of 1,399
1